Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01909258
Other study ID # AOI/2012/PK
Secondary ID 2013-A00232-43
Status Completed
Phase N/A
First received July 18, 2013
Last updated May 19, 2016
Start date January 2015
Est. completion date April 2016

Study information

Verified date May 2016
Source Centre Hospitalier Universitaire de Nimes
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santéFrance: Committee for the Protection of Personnes
Study type Observational

Clinical Trial Summary

The main objective of this study is to describe for the first time the expansion reserve of the pelvic area (measurements using the EOS system) for each of the four morphotypes (Roussouly classification) commonly found in a population of healthy volunteers.


Description:

Secondary objectives:

A. The intra-judge reproducibility and the interrater reliability for the different tools used to measure hip extension will be evaluated. Intra-judge reproducibility (photography) and interrater reliability (goniometry and photography) for the different tools used for measuring hip extension will be evaluated.

B. The concordance between EOS measurements and measurements acquired via goniometry and photography will be evaluated.

C. Describe certain radiographic measurements via the EOS system for the four morphotypes


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria:

- The healthy volunteer must have given his/her informed and signed consent

- The healthy volunteer must be insured or beneficiary of a health insurance plan

Exclusion Criteria:

- The healthy volunteer is participating in another study

- The healthy volunteer is in an exclusion period determined by a previous study

- The healthy volunteer is under judicial protection, under tutorship or curatorship

- The healthy volunteer refuses to sign the consent

- It is impossible to correctly inform the healthy volunteer

- The healthy volunteer is pregnant, parturient, or breastfeeding

- The healthy volunteers had a history of chronic pain or surgery at the hip, the thoracolumbar spine or the sacroiliac area

- The healthy volunteer has a hip, knee or ankle abnormality

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Intervention

Other:
Goniometric measure of pelvic extension reserve.
The pelvic extension reserve (°) is measured via goniometry. The goniometric measurements will be taken once by an investigator on all subjects and once by a different investigator on half of the subjects (with balanced distribution of morphotypes).
Photographic measure of pelvic extension reserve.
The pelvic extension reserve (°) is measured using photography. Photographic measurements will be performed twice one investigator and 1 time by a different investigator (total of three measurements).
EOS measure of pelvic extension reserve.
The pelvic extension reserve (°) is measured using the imaging system EOS. Five X-rays will be made for each volunteer on the EOS system. The first is a frontal shot in a bipedal position, reference snapshot for verifying the absence of spinal deformity or hip pathology. The second and third are profile shots, one on the left and one on the right, whole body, bipedal position; serving as a reference picture. The fourth is profile shot, whole body, with the left hip in hyperextension. For maximum left hip hyperextension, the right leg rests on a step of varying height, and the hip is maximally flexed. The fifth is a profile shot, full body, with the right hip in hyperextension. For a maximum right hip hyperextension, the left leg rests on a step of varying height, and the hip is maximally flexed.

Locations

Country Name City State
France CHU de Montpellier - Hôpital Lapeyronie Montpellier
France CHU de Nîmes - Hôpital Universitaire Carémeau Nîmes Cedex 9

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary EOS measurement of intrinsic reserve extension = angular variation of the sacral slope (left and right sides) = RIEeos baseline (day 0) No
Primary EOS measurement of extrinsic extension reserve = REEeos = angular variation of a specific angle (line joining the center of the sacral plate and the midpoint of the segment involving the center of the femoral head and the line joining this point to the top of the intercondylar knee notch) (left and right sides) Baseline (day 0) No
Primary EOS measurement of global extension reserve = RIEeos + REEeos (left and right sides) Baseline (day 0) No
Secondary Goniometric measurement of global extension reserve (left and right sides) baseline (day 0) No
Secondary Photographic measurement of global extension reserve (left and right sides) baseline (day 0) No
Secondary Roussouly classification: 1, 2, 3 or 4 baseline (day 0) No
Secondary Pelvic incidence (°) Pelvic Incidence is defined as the angle between two lines: the line perpendicular to the sacral endplate at the middle of the sacral endplate to the line between the middle of the sacral endplate to the middle of the femoral heads. Baseline (day 0) No
Secondary Standing sacral slope at rest Baseline (day 0) No
Secondary Standing sacral slope in extension Baseline (day 0) No
Secondary Standing pelvic tilt at rest Baseline (day 0) No
Secondary Standing pelvic tilt in extension Baseline (day 0) No
Secondary Standing anterior pelvic plane Baseline (day 0) No
Secondary The front acetabular inclination while standing Baseline (day 0) No
Secondary The sagittal acetabular inclination while standing Baseline (day 0) No
See also
  Status Clinical Trial Phase
Completed NCT06326723 - Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects Phase 1
Recruiting NCT00001367 - Diagnosis and History Study of Patients With Different Neurological Conditions
Completed NCT02699710 - Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects Phase 1
Completed NCT02231892 - Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study N/A
Not yet recruiting NCT06441916 - Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions Phase 1
Completed NCT03771586 - A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects Phase 1
Not yet recruiting NCT06337422 - Bioequivalence Study of Generic Celecoxib 200 mg Capsules Phase 1
Completed NCT03302182 - Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects Phase 1
Completed NCT05049343 - Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants Phase 1
Recruiting NCT01629108 - Normal Values in Hearing and Balance Testing
Completed NCT02947854 - Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant Phase 1
Completed NCT02534870 - Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects Phase 1
Completed NCT02224053 - Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers Phase 1
Completed NCT01697436 - A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets Phase 1
Completed NCT01676584 - A Study of Single Dose RO6811135 in Healthy Volunteers Phase 1
Completed NCT01684891 - A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers Phase 1
Completed NCT01711762 - A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers Phase 1
Completed NCT01461967 - A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers Phase 1
Completed NCT01579149 - A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent Phase 1
Completed NCT01591850 - A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers Phase 1